Methods for treating visceral fat conditions

a technology for visceral fat and conditions, applied in the direction of biocide, drug composition, metabolic disorder, etc., can solve the problems the presence of visceral fat and its health consequences, so as to reduce the high-density lipoprotein (hdl) cholesterol level, increase and reduce the risk and/or severity

Inactive Publication Date: 2011-06-16
OREXIGEN THERAPEUTICS INC
View PDF99 Cites 30 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In any case, visceral fat and its health consequences can be present.
In any case, visceral fat and its health consequences can be present.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating visceral fat conditions

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0038]A double-blind, placebo-controlled multi-center trial was conducted with 285 healthy, non-diabetic, obese subjects. The subjects were administered either bupropion 200 mg bid, placebo (P), naltrexone 48 mg qd (N1), or bupropion 400 mg with naltrexone 32 mg qd (BN2). 182 subjects completed 24 weeks of treatment. A subset of 60 subjects had dual energy X-ray absorptometry (DEXA) and multislice CT scans to measure body fat, lean tissue and visceral fat (American Diabetes Association Annual Meeting 2007).

[0039]The groups were matched at baseline. Markers of insulin resistance improved more with BN2 than expected from the weight loss alone. A robust effect on decreasing visceral fat was also evident.

TABLE 1Naltrexone &NaltrexoneBupropionBupropionPlacebo48 mg400 mg32 / 400 mgWeight (%) −1.1 ± 0.6 ***−1.74 ± 0.9 ***  −3.14 ± 0.7 ***−7.1 ± 0.7Waist (cm)−1.0 ± 5.4 **−3.8 ± 12.7 −2.9 ± 6.0−5.4 ± 7.6Fasting Glucose1.9 ± 1.3 *3.4 ± 1.7 *   3.5 ± 1.5 *−2.0 ± 1.5(mg / dL)Insulin 0.9 ± 0.9 ** 1....

example 2

[0040]Subjects (n=117) received one of six treatments: two placebos (P+P), placebo and naltrexone (P+Nal), bupropion and placebo (Bup+P), bupropion and naltrexone 48 mg (Bup+Nal 48), bupropion and naltrexone 32 mg (Bup+Nal 32), or bupropion and naltrexone 16 mg (Bup+Nal 16).

[0041]Subjects had a DEXA body scan to measure total body fat, lean tissue and bone mineral content at baseline and at 6 months. Subjects also had a multi-slice CT scan to determine visceral fat volume at the same time points. The mass of selective visceral loss can be calculated based on total fat and the volume of visceral fat.

[0042]The average change in visceral body mass is shown in FIG. 1 for the four treatments. Patients receiving Bup+Nal 32 experienced a dose-related loss in visceral body mass. Statistically significant improvements were also observed in several important metabolic parameters including: plasma glucose, serum insulin and plasma triglycerides.

TABLE 2Baseline Weight, BMI and Weight Circumfere...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
areaaaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

Disclosed are methods and compositions for treating visceral fat conditions and / or metabolic syndrome using combinations of naltrexone and bupropion.

Description

BACKGROUND OF THE INVENTION[0001]1. Field of the Invention[0002]Embodiments of the present invention relate to methods and compositions for reducing visceral fat and / or treating metabolic syndrome.[0003]2. Description of the Related Art[0004]Health risks associated with obesity can depend on how and where the fat is stored. Cutaneous fat refers to fat that is near the skin's surface. Visceral fat, which may also be referred to as intra-abdominal or subcutaneous fat, typically surrounds internal organs. In contrast to subcutaneous fat, visceral fat has been shown to be a risk factor associated with a variety of serious medical disorders.[0005]For example, whether a person is obese (BMI>30) or not, they can still experience visceral fat accumulation in the abdominal cavity (particularly, in the mesentery and / or in the greater omentum). This accumulation, in turn, is often positively correlated with elevated values of serum cholesterol, triglyceride, and / or blood glucose measured by...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/485A61P3/04A61P9/00A61P3/06A61P29/00
CPCA61K31/137A61K31/485A61K2300/00A61P1/02A61P29/00A61P3/00A61P3/04A61P35/00A61P3/06A61P43/00A61P9/00A61P9/10A61P9/12A61P3/10
Inventor TOLLEFSON, GARY
Owner OREXIGEN THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap